Wire flash
Novo Nordisk partners with Anthropic to use Claude AI for drug discovery research
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Novo Nordisk (NVO.N) has announced a partnership with Anthropic to leverage the Claude AI model for advancing drug discovery. The pharmaceutical company will utilize Claude's scientific capabilities to conduct research and development workflows. The collaboration aims to apply artificial intelligence to accelerate the drug development process, though specific financial terms or project timelines were not disclosed in the announcement. This partnership highlights the growing integration of AI models into pharmaceutical research and development.
Source report
Novo Nordisk (NVO.N) has entered into a partnership with Anthropic to leverage the AI model Claude for advancing drug discovery. As part of the collaboration, Novo Nordisk will utilize Claude's scientific capabilities to conduct research and development workflows.
Source
金十数据Neutral / independent
Part of this Story
Novo Nordisk partners with Anthropic to use Claude AI for drug discovery research